Unlike the growth-focused start-ups that have dominated IPO markets for most of the past decade, Arm is more than 30 years old, consistently profitable and had already spent almost two decades as a public company before SoftBank agreed to buy it in 2016.
“If you’re a garden-variety biotech start-up with little revenue, the auditing isn’t that complicated,” said Jay Ritter, an IPO expert at the University of Florida. “Arm has got a complicated business.”
One person close to Arm said its costs were inflated by the need to convert its financial statements from international to US accounting standards.
Deloitte also noted in the prospectus that its audit required “increased extent of effort” because of the complexity of Arm’s customer contracts. Arm does not build and sell chips directly, but earns licence fees and royalties by letting other companies use its designs.
Deloitte did not respond to requests for comment. Arm declined to comment.
On average, companies that raised more than US$1b in IPOs over the past decade spent around US$11.5m on non-underwriting costs, according to the FT analysis.
Alibaba, which raised US$25b in the largest-ever US listing in 2014, spent just over half as much as Arm, with US$46m in non-underwriting fees.
The Arm flotation was closely watched as a test of the health of the broader IPO market, and its warm reception — shares jumped 25 per cent on the first day of trading — has bolstered investors’ hopes of a further wave of new listings, particularly in the tech sector.
However, its unusually high costs provide a reminder that the Cambridge-based business is not a close comparison for most IPO candidates.
One banker who worked on the listing said it was a good sign, but noted that “it’s important everyone tempers the exuberance a little bit”, adding that investors had been focused on “big transactions in big companies” rather than smaller groups.
Written by: Nicholas Megaw
© Financial Times